{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-030137","form_type":"8-K","ticker":"OCGN","cik":"0001372299","company_name":"Ocugen, Inc.","filed_at":"2023-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.728414+00:00","generated_at":"2026-06-11T06:03:51.445247+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Ocugen Q2 net loss $0.10/share; cash at $70.6M; INDs cleared for two gene therapies","bullets":["Cash, cash equivalents & investments $70.6M at June 30, 2023, down from $90.9M at Dec 31, 2022.","Net loss per share $0.10 for Q2 2023 vs $0.09 a year ago; includes $4.4M non-cash impairment on COVAXIN supply asset.","Operating expenses $23.7M (R&D $14.2M, G&A $9.6M); R&D includes $4.4M impairment and disposal loss.","FDA cleared INDs for OCU410 (geographic atrophy) and OCU410ST (Stargardt disease); Phase 1/2 trials planned by year-end.","OCU400 Phase 3 trial expected to begin late 2023/early 2024; updated Phase 1/2 results due this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-030137","json":"https://secwatch.observer/filing/0001628280-23-030137.json","markdown":"https://secwatch.observer/filing/0001628280-23-030137.md","text":"https://secwatch.observer/filing/0001628280-23-030137.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023030137/0001628280-23-030137-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023030137/ocgn-20230821.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T06:03:51.445247+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"660b381af480ff7646fd77fd4be8aa86fab8e4f7","claim":"Ocugen, Inc. reported second quarter ended June 30, 2023 results: net income $0.10 net loss per common share, EPS $0.10 net loss per common share.","evidence_excerpt":"Ocugen reported a $0.10 net loss per common share for the three months ended June 30, 2023 compared to a $0.09 net loss per common share for the three months ended June 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1372299/000162828023030137/0001628280-23-030137-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended June 30, 2023"},{"label":"Net income","value":"$0.10 net loss per common share"},{"label":"EPS","value":"$0.10 net loss per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}